More than half of male patients with classic Fabry disease develop neutralizing antibodies against enzyme replacement therapy (ERT), affecting its effectiveness,…
Articles by Marta Figueiredo, PhD
The first wave of COVID-19Â in Europe severely disrupted access to care and raised stress and anxiety in people with…
Switching from enzyme replacement therapy (ERT) to Galafold (migalastat) is a valid and safe therapeutic option for Fabry disease…
A common GLA mutation is highly associated with the development of Fabry disease in both men and women, and…
Nearly half of Fabry patients have amenable or responsive mutations to Galafold (migalastat) but show different responses to the…
Fabry Stabilization index (FASTEX) is a valid, specific, and sensible instrument to accurately assess disease stability/progression in people with…
Use of Replagal — an enzyme replacement therapy (ERT) — during pregnancy and breastfeeding by women with Fabry disease appears…
Adjusting the dose of enzyme replacement therapy (ERT) for each patient may be essential to achieve complete neutralization of…
The absence of white matter lesions (WMLs) in two specific regions of the brain may help physicians distinguish Fabry disease…
Protalix BioTherapeutics‘ investigational therapy PRX-102 (pegunigalsidase alfa) improved kidney function in Fabry disease patients, according to preliminary Phase 3 clinical…